1. Home
  2. EXAS vs PSN Comparison

EXAS vs PSN Comparison

Compare EXAS & PSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • PSN
  • Stock Information
  • Founded
  • EXAS 1995
  • PSN 1944
  • Country
  • EXAS United States
  • PSN United States
  • Employees
  • EXAS N/A
  • PSN N/A
  • Industry
  • EXAS Medical Specialities
  • PSN EDP Services
  • Sector
  • EXAS Health Care
  • PSN Technology
  • Exchange
  • EXAS Nasdaq
  • PSN Nasdaq
  • Market Cap
  • EXAS 10.6B
  • PSN 8.6B
  • IPO Year
  • EXAS N/A
  • PSN 2019
  • Fundamental
  • Price
  • EXAS $57.01
  • PSN $88.86
  • Analyst Decision
  • EXAS Strong Buy
  • PSN Strong Buy
  • Analyst Count
  • EXAS 21
  • PSN 12
  • Target Price
  • EXAS $67.86
  • PSN $90.09
  • AVG Volume (30 Days)
  • EXAS 2.3M
  • PSN 1.2M
  • Earning Date
  • EXAS 11-04-2025
  • PSN 11-05-2025
  • Dividend Yield
  • EXAS N/A
  • PSN N/A
  • EPS Growth
  • EXAS N/A
  • PSN 23.64
  • EPS
  • EXAS N/A
  • PSN 2.23
  • Revenue
  • EXAS $2,939,949,000.00
  • PSN $6,683,116,000.00
  • Revenue This Year
  • EXAS $16.68
  • PSN N/A
  • Revenue Next Year
  • EXAS $12.08
  • PSN $5.98
  • P/E Ratio
  • EXAS N/A
  • PSN $39.27
  • Revenue Growth
  • EXAS 12.55
  • PSN 9.22
  • 52 Week Low
  • EXAS $38.81
  • PSN $54.56
  • 52 Week High
  • EXAS $72.83
  • PSN $114.68
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 68.53
  • PSN 72.66
  • Support Level
  • EXAS $52.85
  • PSN $79.07
  • Resistance Level
  • EXAS $54.74
  • PSN $83.13
  • Average True Range (ATR)
  • EXAS 1.40
  • PSN 2.42
  • MACD
  • EXAS 0.17
  • PSN 0.86
  • Stochastic Oscillator
  • EXAS 93.39
  • PSN 94.00

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.

Share on Social Networks: